Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.46 |
| ▸ | ITGAV | P06756 | 10/20 | 0.46 |
| ▸ | F2 | P00734 | 8/20 | 0.41 |
| ▸ | TMPRSS6 | Q8IU80 | 8/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650233 | 0.87 | ITGB3 (0.48) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL4650447 | 0.87 | ITGB3 (0.50) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL4650264 | 0.82 | NPY5R (0.52) | ITGB3ITGA2BITGAVHTTSMN1; SMN2 | |
| SCHEMBL4650967 | 0.82 | ITGB3 (0.44) | ITGB3ITGA2BITGAV | |
| SCHEMBL7114722 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL4650222 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL4650994 | 0.81 | ITGB3 (0.57) | ITGB3ITGA2BITGAVF2TMPRSS6 | |
| SCHEMBL4650241 | 0.81 | ITGB3 (0.45) | ITGB3ITGA2BITGAV | |
| SCHEMBL4651098 | 0.81 | HSD17B10 (0.45) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL4651218 | 0.80 | ITGB3 (0.48) | ITGB3ITGA2BITGAVF2TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | claimed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | ITGB3 3242/4885ITGA2B 2530/4885ITGAV 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.